Beta2-microglobulin amyloid fragment organization and morphology and its comparison to Abeta suggests that amyloid

Jie Zheng1, Hyunbum Jang, Ruth Nussinov

  • 1Department of Chemical and Biomolecular Engineering, The University of Akron, Akron, Ohio 44325, USA. zhengj@uakron.edu

Biochemistry
|January 25, 2008
PubMed

Insights

Molecular dynamics simulations reveal that beta2-microglobulin (beta2-m) K3 oligomers form stable linear-like amyloid structures, not annular ones, driven by hydrophobic interactions. This highlights sequence-specific aggregation pathways in amyloid formation.

Area of Science:

  • Biophysics
  • Structural Biology
  • Computational Chemistry

Background:

  • Dialysis-related amyloidosis is linked to beta2-microglobulin (beta2-m) deposits.
  • The oligomeric structure of beta2-m fragments is crucial for understanding amyloid formation.
  • Previous studies have solved the structure of a beta2-m fragment (K3).

Purpose of the Study:

  • To model equilibrium structures of K3 oligomers using molecular dynamics (MD).
  • To investigate the influence of organization (single/double layers) and morphology (linear/annular) on K3 oligomers.
  • To elucidate the key forces driving amyloid fibril formation and morphology.

Main Methods:

  • All-atom molecular dynamics (MD) simulations.
  • Modeling of wild-type and mutant K3 oligomers with varying organizations and morphologies.
  • Analysis of sheet-to-sheet association forces, focusing on N-terminal-N-terminal (NN) interfaces.

Main Results:

  • Stable linear-like K3 oligomers observed, including single-layered parallel beta-sheets and double-layered antiparallel beta-sheets via NN interface.
  • No stable annular K3 oligomer structures were found, attributed to electrostatic repulsion from charged residues.
  • Double-layered oligomers with NN interfaces were energetically favored over those with C-terminal-C-terminal (CC) or C-terminal-N-terminal (CN) interfaces.

Conclusions:

  • Linear-like structures with parallel beta-strands and antiparallel beta-sheets represent plausible intermediate states for K3 beta2-m amyloid fibrils.
  • Hydrophobic interactions and side-chain packing are critical for stabilizing K3 oligomers.
  • Amyloid morphology and aggregation pathways are sequence-specific, differing significantly between beta2-m and Abeta despite similar secondary structures.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Protein Organization01:13

Protein Organization

Overview